Clinical trial
Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or…
NCT00466583 · Enzon Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00466583 |
|---|---|
| Title | Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma |
| Official title | A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of EZN-2968, a Locked Nucleic Acid Antisense Oligonucleotide Against Hypoxia-Inducible Factor-1α, Administered as a Weekly 2-Hour Intravenous Infusion in Adult Patients With Advanced Solid Tumors or Lymphoma |
| Lead sponsor | Enzon Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Lymphoma |
| Intervention type | Drug |
| Interventions | Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN) |
| Enrollment | 52 |
| Start date | Mar 1, 2007 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Apr 27, 2007 |
| Last update posted | Jul 7, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: